替诺福韦酯治疗HBeAg阳性慢性乙型肝炎患者的疗效及对肝功能指标的影响

目的探讨替诺福韦酯治疗HBeAg阳性慢性乙型肝炎患者的疗效及对肝功能指标的影响。方法选取2017年2月至2018年3月本院收治的126例HBeAg阳性慢性乙型肝炎患者,按照年龄、性别组间具有可比性原则分为对照组与观察组,各63例。对照组予以恩替卡韦治疗,观察组予以替诺福韦酯治疗,比较两组治疗前后肝功能指标及ALT复常率、HBV DNA转阴率、HBeAg转阴率。结果治疗后,两组AST、ALT、TBiI均低于治疗前,且观察组低于对照组,ALB高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);观察组ALT复常率、HBV DNA阴转率、HBeAg转阴率均高于对照组,差异有统计学意义(P<0.05)。结论相比恩替卡韦治疗,替诺福韦酯治疗HBeAg阳性慢性乙型肝炎患者,可有效改善肝功能,提高HBV DNA阴转率及HBeAg阴转率。

The effect of tenofovir dipivoxil and entecavir in the treatment of HBeAg positive chronic hepatitis B

Objective To explore the effect of tenofovir dipivoxil and entecavir in the treatment of HBeAg positive chronic hepatitis B.Methods From February 2017 to March 2018,126 cases of HBeAg-positive chronic hepatitis B treated in our hospital were selected,and they were divided into control group and observation group according to the principle of comparability in age and gender between two groups,with 63 cases in each group.The control group was treated with entecavir and the observation group was treated with tenofovir dipivoxil.The liver function indexes,ALT recovery rate,HBV DNA negative conversion rate and HBeAg negative conversion rate were compared between the two groups before and after treatment.Results After treatment,the AST,ALT and TBiI of both groups were lower than before treatment,and the observation group was lower than the control group,ALB was higher than before treatment,and the observation group was higher than the control group,the difference was statistically significant(P<0.05).The ALT normalization rate,HBV DNA negative conversion rate,HBeAg negative conversion rate of the observation group were all higher than those of the control group,the difference was statistically significant(P<0.05).Conclusion Compared with entecavir treatment,treatment with tenofovir dipivoxil for HBeAg-positive chronic hepatitis B patients can effectively improve liver function,increase HBV DNA negative conversion rate and HBeAg negative conversion rate.